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In Germany, IQWIG has proposed to use correlations between surrogate endpoints 
and patient relevant outcomes to determine value of cancer drugs. Due to increased 
cost pressure on payers, such models are likely to inspire novel reimbursement 
schemes for other branded products. ConClusions: Cancer drug reimbursement 
models are setting new benchmark for payers to manage access and control costs. 
These models have significant implications for other expensive branded products.
PCN205
The RelaTioNshiP BeTweeN suBmiTTed liNe of TheRaPy aNd 
ReimBuRsemeNT deCisioNs iN solid sTaTe TumoR CaNCeR dRugs
Jao R., Jaksa A., Ho Y.S., Daniel K.
Context Matters, Inc., New York, NY, USA
objeCtives: To explore the relationship between lines of therapy and submission 
for reimbursement across disease conditions and types of therapy. Methods: This 
study looked at 252 Health Technology Assessments from eight agencies: CADTH, 
CCO, HAS, HIS, NICE, PBAC, SMC, and pCODR. The data covered 41 drugs across 
seven solid-state tumor cancer conditions. Results: Of the 41 drugs, 27% (11/41) 
were initially submitted for first-line therapy and 73% (8/11) were recommended 
for reimbursement. Similarly, 32% (13/41) were initially submitted for second-line 
therapy and 77% (10/13) were recommended for reimbursement. Cytotoxic drugs 
were most likely to be reviewed initially for first-line therapy at 35% (7/20) and 
second-line therapy at 25% (5/20); targeted therapies were most likely to be reviewed 
initially for second-line therapy at 38% (8/21) and adjuvant therapy at 24% (5/21). 
The percentage of drugs reviewed for two or more lines of therapy varied greatly 
across conditions. Colorectal Cancer, SCLC, and NSCLC had the greatest percentages 
of drugs reviewed for 2+ lines of therapy with 100% (4/4), 100% (1/1), and 83% (5/6), 
respectively. Melanoma, Prostate Cancer, and Ovarian had the lowest percentages 
with 0% (0/2), 14% (1/7), and 40% (2/5), respectively. Additionally, there was a positive 
correlation (r= 0.9) between the number of drugs reviewed and number of lines of 
therapy covered per disease condition. ConClusions: There was no discernable 
difference in the rate of reimbursement between drugs initially submitted for first-
line therapy or second-line therapy. There were, however, differences in various 
trends across disease conditions and between types of therapy. Future research will 
focus on trends across agencies and will include a larger sample size covering more 
conditions as well as investigational case studies on frequently reviewed drugs.
PCN206
CliNiCal aNd CosT-effeCTiveNess of NoN-PegylaTed liPosomal 
doxoRuBiCiN foR NoN-hodgkiN lymPhoma: a sysTemaTiC Review
Burda A.1, Zaremba A.1, Lubonski J.2, Matusewicz W.1
1Agency for Health Technology Assessment in Poland (AOTM), Warsaw, Poland, 2General Hospital 
in Legnica, Legnica, Poland
objeCtives: To systematically review the currently available clinical and cost-
effectiveness evidence of non-pegylated liposomal doxorubicin (NPLD) for 
non-Hodgkin lymphoma (nHL). The hypothesis under verification was that the 
administration of NPLD lowers the cardiotoxicity typical for conventional anthra-
cyclines while being able to sustain the clinical effect of treatment. Methods: 
A systematic literature search was conducted for clinical and cost-effectiveness 
data for the nHL population treated with NPLD, using the main medical data-
bases (PubMed, EMBASE, Cochrane Library). In addition, clinical trial registries 
were searched, reference lists of included studies and reviews were screened for 
missed studies. Searches took place in September 2012. Results: The review 
generated 9 one-arm clinical trials and 1 retrospective study which met the inclu-
sion criteria. One comparative parallel trial comparing R-CHOP with R-COMP in 
the DLBCL population is ongoing, with no results published. Generally, available 
evidence is poor – studies identified are characterized by many limitations, i.e.: 
small and heterogeneous study populations, relatively short observation period, 
not always specified inclusion and exclusion criteria, diversified treatment regi-
mens (with R-CHOP dominating), shortened or/and presented selectively safety 
data. The majority of studies was performed in the DLBCL population. Cumulative 
interpretation of data was hindered due to essential differences in between trials. 
Lowering of LVEF was observed with a frequency of 0% to 31,7% of cases, while 
symptomatic lowering of LVEF with the development of chronic ischemic heart 
disease occurred with the frequency of 0 to 10%. The second most frequent car-
diological event observed was arrhythmia. Clinical efficacy focused on surrogate 
endpoints (radiological responses), defined differently in between trials. No eco-
nomic evaluations studies were found. ConClusions: There is limited evidence 
on the effectiveness and safety of NPLD in patients with nHL due to the lack of 
well-designed and well-reported comparative studies. Further research is needed 
to explore the hypothesis in question.
PCN207
imPaCT of ReCommeNded PhaRmaCeuTiCals oN CaNCeR moRTaliTy: 
aNalysis of Real-life daTa
Wilson T., Hamerslag L.
Costello Medical Consulting Ltd., Cambridge, UK
objeCtives: To ascertain whether there were any trends in cancer mortality after 
hospital admittance and diagnosis that could be linked to recent approval of thera-
pies by the National Institute for Health and Care Excellence (NICE). Methods: 
Using information provided by Hospital Episode Statistics and the Office of National 
Statistics, yearly mortality data from both the inpatient and outpatient population 
between 2007 and 2010 were extracted. An analysis of 30-, 60-, and 90-day mortal-
ity following admittance to hospital was undertaken for malignancies which had 
seen therapies approved by NICE after 2006. Results: Of the 37 cancer therapies 
assessed by NICE between 2006 and 2010 inclusive, 27 were recommended. Patients 
with lung cancer were found to experience one of the highest mortality rates over-
all. Interestingly, lung cancer also saw the largest number of therapies approved 
between 2006 and 2010 (7), along with a steady decline in the annual 90-day mortal-
ity over the three year period (29.6%, 28.4% and 27.1% in 2007-08, 2008-09 and 2009-
to chemotherapy. The algorithm was validated against a PSA-based definition of 
CRPC (at least two PSA increases following castration or new metastases while 
on hormone therapy). Results: A total of 269 patients met inclusion criteria and 
had 3 or more PSA measurements. The two methods agreed in 88% of patients; 220 
(81.8%) were identified as CRPC by both methods and 17 (6.3%) were identified as not 
castration resistant by both methods. A statistical comparison of the two methods 
yielded a Cohen’s kappa of 0.4491, indicating moderate agreement. ConClusions: 
The algorithm was concordant with a PSA-based definition of CRPC and serves as 
a new tool to identify CRPC patients using claims data. Future validation against a 
different data source is needed.
PCN202
iNCReased Risk of CaNCeR iNCideNCe assoCiaTed wiTh RePeaT mediCal 
imagiNg: desigNiNg BeTTeR CliNiCal TRial PRoToCols
Zowall H., Brewer C., Deutsch A.
Zowall Consulting Inc., Westmount, QC, Canada
objeCtives: To assess the potential increase in lifetime attributable risk (LAR) 
of cancer incidence due to repeated exposure to medical imaging procedures for 
participants in clinical trials. Methods: Medical imaging in clinical trials has 
grown exponentially in the last decade. We have developed an individual-based 
state-transition model to estimate the LAR of radiation-related cancer following a 
patient’s exposure history, and site-specific dose according to age and gender. Monte 
Carlo simulations to vary effective doses, risk model coefficients, and the period 
for radiation-related cancer latency were performed. Results: We examined two 
scenarios in a three year hypothetical clinical trial: minimal exposure describing 
a subject’s radiation exposure as one abdominal CT scan per year; and frequent 
exposure consisting of five abdominal CT scans per year. For a 30 year old female the 
LAR of cancer incidence increased from 46 per 100,000 population in the minimal 
exposure scenario to 229 per 100,000 in the frequent exposure scenario. For a 30 
year old male, the risk increased from 36 to 179 per 100,000. At age 30, females had 
a 30% higher risk than males, however, cancer incidence at ages 50, and 70 were 
similar for both sexes. At age 50 the LAR of cancer incidence increased from 31 to 
151 per 100,000. At age 70 the risk increased from 15 to 71 per 100,000. The LAR of 
cancer incidence was one third lower in 70 year olds than in 30 year olds, and half 
the rate of 50 year olds. ConClusions: Although the LAR of cancer incidence of a 
single exposure seems to be relatively small, clinical trials that involve a compara-
tively large number of imaging procedures can lead to significantly higher risks. 
Examinations that deliver relatively high doses of radiation, such as CT, need to 
be clinically justified.
PCN203
TReNds iN ChemoTheRaPy seTTiNg aNd CosTs fRom 2005 To 2012: a Case 
sTudy usiNg BevaCizumaB
Foley K.
Truven Health Analytics, Cambridge, MA, USA
objeCtives: The rising costs of cancer care are a major focus for clinicians, payers 
and patients. This analysis examines trends in bevacizumab chemotherapy admin-
istration and drug reimbursement. Methods: Using the MarketScan© Research 
Databases, administrations of bevacizumab were identified from 1/1/2005 through 
12/31/2012 for patients with commercial or employer-sponsored supplemental 
Medicare insurance. Bevacizumab claims were excluded if the claim had a diagnosis 
related to eye disease or the reimbursed amount was < $100. All claims were iden-
tified as occurring in an office-based setting (OBS), an outpatient hospital setting 
(OHS) or other setting. Results: The percent of bevacizumab claims occurring in OHS 
increased from 6 to 34% among Medicare claims, and from 14 to 42% among commer-
cial claims from 2005 to 2012. Medicare median drug reimbursement was $257 more 
for OHS than OBS in 2005, increasing to a difference of $3,022 in 2009 and declining 
to $1,722 in 2011 before narrowing to $165 in 2012. Medicare median reimbursements 
for chemotherapy administration in OHS were $408 more than OBS in 2005, dropping 
to a difference of $97 in 2008 and ending at $165 in 2012. Commercial differences in 
drug reimbursement for OHS and OBS settings continuously increased from $885 in 
2005 to $3714 in 2011, declining slightly to $3676 in 2012. Differences in chemotherapy 
administration reimbursement were $176 more for OHS than OBS in 2005, the dif-
ference decreasing to $103 in 2007 and increasing to $236 in 2012. ConClusions: 
Although the difference in reimbursements to OHS and OBS has decreased over time 
for Medicare, the differences across settings for commercial insurance increased over 
time with a slight indication that cost increases are slowing. The higher reimburse-
ments in OHS combined with the shift from OBS to OHS over the past 7 years has 
implications for the growth in cancer costs over the past decade.
PCN204
Novel maRkeT aCCess models foR CaNCeR dRugs
Aggarwal S., Kumar S., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
objeCtives: Cancer drugs are the world’s highest selling category of therapeutic 
products. Due to their premium price and budget impact, several new drug reim-
bursement models have been implemented worldwide by public and private pay-
ers. These models have potential implications for coverage and reimbursement 
of all branded products. This study reviewed recent cancer drug reimbursement 
models and developed lessons and implications for future products. Methods: 
Reviewed cancer drug reimbursement schemes in developed and emerging markets. 
Interviewed payers and KOLs to develop lessons and implications for future prod-
ucts. Results: Public and private payers worldwide have implemented several new 
models for cancer drug reimbursement to manage budgets and control costs. In the 
US, private payers are piloting single source compendia and third party protocols (eg. 
P4 Oncology) to limit off-label use of cancer drugs. In the UK, NICE has successfully 
negotiated lower price and discounts for first few cycles of therapy. In Italy, AIFA has 
implemented registry based patient access for cancer drugs. In India, several manu-
facturers have implemented novel pricing strategy for first few cycles of therapy. 
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and a combination of tegafur, gimeracil and oteracil. Across these oncology assess-
ments a total of 19 patient subgroups have been evaluated. Eleven subgroups (58%) 
showed an additional benefit according to the G-BA. Eight subgroups (42%) received 
the rating “no additional benefit” or “less benefit than comparator”. The compara-
tors chosen by G-BA within subgroups vary widely depending on the indication. 
Key factors for the positive outcome of these assessments were increased overall 
survival, reduction of symptoms or improved quality of life. Main reasons for the 
G-BA to attest no additional benefit include inappropriate indirect comparison and 
lack of adequate patient subgroup analysis. ConClusions: Analysis of HTA reports 
in oncology shows that while overall survival is a strong end point, also increased 
quality of life and reduced side-effects can be sufficient to achieve a beneficial 
outcome (crizotinib: considerable benefit). Importantly, the provided data must be 
applicable to the German regulations under AMNOG, showing clinical evidence 
against the specified comparator. The amount of the additional benefit plays an 
important role in the reimbursement amount negotiations following the definition 
of the additional benefit by the G-BA.
PCN211
healTh TeChNology assessmeNT: is iT The RighT PieCe foR The 
JoRdaNiaN healTh CaRe Puzzle?
Al Rabayah A.A., Jaddoua S.
King Hussien Cancer Center, Amman, AL, Jordan
objeCtives: To study the pharmaceutical reimbursement/Coverage decision 
making processes in Jordan to highlight the importance of conducting formalized 
technology assessments Methods: To review publically available data regarding 
the reimbursement/Coverage decision making processes in Jordan through search-
ing related organization’s websites and publically available regulations. Results: 
Jordan is characterized with a fragmented health care system. Pharmaceutical 
registration and pricing are under the responsibility of the JFDA. Furthermore, it 
is responsible about medication selection for the Rational Drug List (the national 
formulary). The medication supply chain differs between the public and the private 
sectors in term of process and out puts. The medication selection process is not 
governed by criteria and not empowered by an independent review body to support 
decision making by the national appraisal committee (national P&T). The rational 
drug list is publically available but without details of the decision or the processes 
of decision making process. Listing of new medication is wide without indication 
specification or date of listing. The role of cost-effectiveness is limited and the ten-
der prices are not linked to any type of cost effectiveness analysis ConClusions: 
The National Agenda, the National health Policy and the National Drug Policy 
tackled the high health expenditure in Jordan as an essential priority. This chal-
lenged is due to the characteristics of the Jordanian health care system that is 
fragmented with a divided funding system between public and private sectors. A 
more formalized medication selection processes empowered with drug information 
services that provide evidence based data and analysis in the form of technology 
assessment would play a role in decreasing health care expenditures. All of these 
recommendations should move parallel with improving the level of transparency 
and patient engagement.
PCN214
ePidemiology foR oNCologiCal dRugs RegaRdiNg The BeNefiT dossieR 
PRePaRaTioN iN geRmaNy
Kürschner N., Schmitter S.
Pfizer Deutschland GmbH, Berlin, Germany
objeCtives: An early benefit assessment of drugs after launch has been imple-
mented since 2011 in Germany. The Institute for Quality and Efficiency in Health Care 
(IQWiG) assesses the benefit of the drug based on a dossier submitted by the phar-
maceutical manufacturer. Based on this assessment and the statements by industry, 
scientific community and patient organizations the Federal Joint Committee (G-BA) 
reviews and decides on the extent of the additional benefit. The dossier needs also 
to contain information about the number of patients treated with the new drug. The 
objective is to investigate the sources considering the calculation of patient numbers 
for oncological drugs. Methods: A review of oncological drugs which passed through 
the benefit assessment was conducted to evaluate which data sources and methods 
were used to calculate the potential patient number. The results were compared with 
IQWiG’s assessment and the final decision by G-BA, to detect possible methodologi-
cal difficulties. Results: The data sources regarding German epidemiological data 
were mainly collected through publicly available sources such as national and local 
cancer registries. Difficulties occurred with small cancer entities or when specific 
data regarding patient subpopulations (e.g. through age, tumor stages, ECOG perfor-
mance status or previous therapies) was needed. The pharmaceutical manufacturer’s 
calculations were often challenged by IQWiG and G-BA without suggesting a precise 
alternative or more suited data source. ConClusions: The data collection and data 
availability within the benefit dossier process for oncological drugs is in most cases 
challenging and the efforts needed should not be underestimated. Authorities, indus-
try and medical community should work on a common solution for a more valid and 
reliable calculation of the potential patient number in oncology.
PCN215
eCoNomiCal losses due To disaBlemeNTPaReNTs CaRRiNg foR ChildReN 
wiTh oNCohemaTologiCal diseases
Ganieva D.1, Zhukovskaya E.1, Spichak I.2
1Federal Scientific Centre of Children Hematology, Oncology, Immunologyl, Moskow, Russia, 
2Medical Academy, Chelyabinsk, Russia
objeCtives: Socio-economic phenomena, caused by disease of children are reflected 
primarily in the formation of non-medical costs. Methodology for calculation of non-
medical costs includes a number of parameters, including the cost of lost output 
by persons caring for children during the treatment period. Methods: The study 
involved patients from Oncohematological Chelyabinsk Center for Children and 
Adolescents behalf of prof. V. Gerein been treated in the period from 2008 to 2013. 
10, respectively). Similarly, patients admitted to hospital with oesophageal cancer 
experienced a high 90-day mortality rate, ranging from 22% to 21.9% in 2007-08 and 
2009-10, respectively. However, between 2006 and 2010, no therapies were submitted 
for NICE appraisal for oesophageal cancer, suggesting that there may have been a 
lack of research interest and potentially explaining why there was no substantial 
decrease in mortality from 2007, as compared to indications where therapies had 
been approved, such as lung, colon and breast cancer. ConClusions: The recom-
mendation of therapies and their uptake in the UK may at least partially explain the 
trends noted in this study, although other factors such as delay in therapy uptake 
and off-label use may also need to be taken into account.
PCN208
do NiCe evideNCe Review gRouPs (eRg) foCus oN diffeReNT asPeCTs of 
maNufaCTuReR suBmissioNs iN oNCology?
Heemstra L., Sweeney N., Van Engen A.
Quintiles, Hoofddorp, The Netherlands
objeCtives: Evidence Review Groups (ERGs) provide a critical appraisal of the manu-
facturer submission in the NICE single technology appraisal (STA) process. As the aca-
demic centres may differ in experience and methodology, the objective of this study was 
to evaluate whether the focus areas and key criticisms differ between ERGs. Methods: 
The NICE website was searched for all NICE oncology STAs, published between June 
2010 and June 2013. The ERG reports were retrieved, and the main critiques were cat-
egorised for the five centres that performed the most evaluations. The focus areas of the 
ERGs were further studied. Results: A total of 27 STAs were identified with evaluations 
performed by 9 different ERGs. The most evaluations were performed by Liverpool (9), 
followed by Sheffield (4), and PenTAG, West Midlands and York (3 evaluations each). All 
ERGs would report uncertainties related to the extrapolation and gain in overall survival 
(OS), maturity of data, trial comparator, and the quality of life (QoL) data. In addition all 
critiques covered submission quality and disease specific challenges, yet variation was 
found in focus area between ERGs. For example a specific focus area of Liverpool was 
the OS modelling method. Proposed changes to survival modelling included separating 
the survival curves for pre- and post-progression, and removing any survival advan-
tage post-progression where this was considered inappropriate. Comments from other 
agencies on OS were mainly limited to the choice of parametric survival function. Other 
areas that differed between ERGs were the systematic review methods (more often 
reported by Sheffield) and comments on the QoL data (York). ConClusions: Although 
all ERGs focus on uncertainty around the evidence and quality of the manufacturer 
submissions, the focus areas differed between the groups. The key difference seems 
to relate to research focus of the academic centre.
PCN209
Review of NiCe TeChNology aPPRaisals iN oNCology: how does 
CliNiCal evideNCe ChaNge oveR Time?
Dequen P., Cooper N.J., Abrams K.R.
University of Leicester, Leicester, UK
Drug licensing and reimbursement authorities worldwide are considering new 
ways to stimulate market access for innovative medicines such as accelerated 
approval and conditional coverage. Early release of pharmaceuticals calls for more 
responsive decision-making alongside continuous evidence generation through-
out clinical development. We explore whether changing trends in clinical evidence 
considerations for health technology assessment (HTA) by the National Institute 
for Health and Care Excellence (NICE) may help inform future evidence require-
ments for rapid and early HTA. objeCtives: We investigate how the submission 
and acceptability of clinical evidence for single, multiple and repeated assessments 
of cancer drugs by NICE have changed in the past decade. Methods: We reviewed 
technology appraisals published online since February 2002 by NICE for pharma-
ceuticals in oncology. Information regarding the clinical evidence included and the 
methods used to analyse relative treatment effects across relevant comparators 
was extracted. Manufacturer submissions, assessment reports, and final appraisal 
determinations were considered for longitudinal comparison. Results: Out of a 
total of 254 appraisals identified since 2002, 85 assessed cancer drugs and 76 of 
these were included for review based on available documentation. Only 11 prod-
ucts had been re-assessed to date with initial guidance superseded by a multiple 
technology appraisal or clinical guideline. We found a greater reliance on phase 
II and observational data in recent appraisals, particularly for novel therapies in 
areas of high unmet need. Limited data was also accompanied by an increase use 
of surrogate outcomes and extrapolation of observed short-term clinical benefits. 
Recent submissions were also marked by the uptake of network meta-analysis 
methodologies. ConClusions: NICE has previously recommended cancer drugs 
based on immature clinical data allowing for considerable uncertainty in ‘real-
world’ effectiveness estimates. However, these examples remain the exception to 
the rule; moreover our review highlighted a need for methodological development 
to deal with early clinical evidence.
PCN210
g-Ba assessmeNTs of oNCology TRials: is iNCReased oveRall suRvival 
a “musT have”?
Schuchardt M.1, Nijhuis T.1, Friedmann B.2
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Mannheim, Germany
objeCtives: Objective of this research was to provide an overview of Health 
Technology Assessments (HTAs) in oncology after introduction of AMNOG in 
Germany. Methods: Quintiles’ HTA database (HTA Watch) has been used to ana-
lyse HTAs in Germany. The timeframe chosen for analysis was 1st of January 2011 
to 24th of June 2013. All reports have been analysed in detail to reveal key factors for 
success or failure, which are presented in the following. Results: Since introduc-
tion of AMNOG in 2011, thirty percent (13 out of 43) of all completed assessments by 
the G-BA (Federal Joint Committee) evaluated cancer drugs. The products assessed 
were abiraterone acetate, axitinib, brentuximab vedotin, cabazitaxel, crizotinib, 
decitabine, eribulin, ipilimumab, pixantrone, ruxolitinib, vandetanib, vemurafenib 
